AVTR vs. ILMN, WAT, RVTY, BIO.B, BIO, LH, HOLX, BMRN, TEVA, and BGNE
Should you be buying Avantor stock or one of its competitors? The main competitors of Avantor include Illumina (ILMN), Waters (WAT), Revvity (RVTY), Bio-Rad Laboratories (BIO.B), Bio-Rad Laboratories (BIO), Laboratory Co. of America (LH), Hologic (HOLX), BioMarin Pharmaceutical (BMRN), Teva Pharmaceutical Industries (TEVA), and BeiGene (BGNE). These companies are all part of the "medical" sector.
Illumina (NASDAQ:ILMN) and Avantor (NYSE:AVTR) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, community ranking, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability.
Avantor has higher revenue and earnings than Illumina. Illumina is trading at a lower price-to-earnings ratio than Avantor, indicating that it is currently the more affordable of the two stocks.
Avantor has a net margin of 3.79% compared to Avantor's net margin of -28.71%. Illumina's return on equity of 13.01% beat Avantor's return on equity.
89.4% of Illumina shares are owned by institutional investors. Comparatively, 95.1% of Avantor shares are owned by institutional investors. 0.2% of Illumina shares are owned by company insiders. Comparatively, 1.3% of Avantor shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Illumina has a beta of 1.2, indicating that its stock price is 20% more volatile than the S&P 500. Comparatively, Avantor has a beta of 1.36, indicating that its stock price is 36% more volatile than the S&P 500.
In the previous week, Illumina had 31 more articles in the media than Avantor. MarketBeat recorded 37 mentions for Illumina and 6 mentions for Avantor. Illumina's average media sentiment score of 1.04 beat Avantor's score of 0.34 indicating that Avantor is being referred to more favorably in the news media.
Illumina received 910 more outperform votes than Avantor when rated by MarketBeat users. Likewise, 65.69% of users gave Illumina an outperform vote while only 63.64% of users gave Avantor an outperform vote.
Illumina presently has a consensus target price of $164.65, indicating a potential upside of 48.20%. Avantor has a consensus target price of $26.71, indicating a potential upside of 9.17%. Given Avantor's higher probable upside, equities research analysts clearly believe Illumina is more favorable than Avantor.
Summary
Avantor beats Illumina on 13 of the 18 factors compared between the two stocks.
Get Avantor News Delivered to You Automatically
Sign up to receive the latest news and ratings for AVTR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AVTR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
